Superior Peptide


MK- 2866 (Ostarine)

Results 1 to 4 of 4
  1. #1
    Senior Member
    BOARD REP
    Elvia1023's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    United Kingdom
    Posts
    518
    Rep Points
    402616

    MK- 2866 (Ostarine)






    Another name for it is enobosarm. I will post some studies highlighting it's effectiveness.

    The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
    Dalton JT1, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS.
    Author information

    1GTx, Inc., 175 Toyota Plaza, Memphis, TN 38103 USA.

    Abstract
    BACKGROUND:
    Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation.
    METHODS:
    A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women. The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry, and secondary endpoints included physical function, body weight, insulin resistance, and safety.
    RESULTS:
    GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups.
    CONCLUSION:
    GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention and/or treatment of muscle wasting associated with cancer and other chronic diseases.



    Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
    Dobs AS1, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS.
    Author information

    1Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. adobs@jhu.edu

    Abstract
    BACKGROUND:
    Cancer-induced muscle wasting begins early in the course of a patient's malignant disease, resulting in declining physical function and other detrimental clinical consequences. This randomised, double-blind, placebo-controlled phase 2 trial assessed the efficacy and safety of enobosarm, a selective androgen receptor modulator, in patients with cancer.
    METHODS:
    We enrolled male (>45 years) and female (postmenopausal) patients with cancer who were not obese and who had at least 2% weight loss in the previous 6 months. Participants were randomly assigned (1:1:1 ratio, by computer generated list, block size three, stratified by cancer type) to receive once-daily oral enobosarm 1 mg, 3 mg, or placebo for up to 113 days at US and Argentinian oncology clinics. The sponsor, study personnel, and participants were masked to assignment. The primary endpoint was change in total lean body mass from baseline, assessed by dual-energy x-ray absorptiometry. Efficacy analyses were done only in patients who had a baseline and an on-treatment assessment in the protocol-specified window of within 10 days before baseline or first study drug, and within 10 days of day 113 or end of study (evaluable efficacy population). Adverse events and other safety measurements were assessed in the intention-to-treat (safety) population. This trial is registered with ClinicalTrials.gov, number NCT00467844.
    FINDINGS:
    Enrolment started on July 3, 2007, and the last patient completed the trial on Aug 1, 2008. 159 patients were analysed for safety (placebo, n=52; enobosarm 1 mg, n=53; enobosarm 3 mg, n=54). The evaluable efficacy population included 100 participants (placebo, n=34; enobosarm 1 mg, n=32; enobosarm 3 mg, n=34). Compared with baseline, significant increases in total lean body mass by day 113 or end of study were noted in both enobosarm groups (enobosarm 1 mg median 1&middot;5 kg, range -2&middot;1 to 12&middot;6, p=0&middot;0012; enodosarm 3 mg 1&middot;0 kg, -4&middot;8 to 11&middot;5, p=0&middot;046). Change in total lean body mass within the placebo group (median 0&middot;02 kg, range -5&middot;8 to 6&middot;7) was not significant (p=0&middot;88). The most common serious adverse events were malignant neoplasm progression (eight of 52 [15%] with placebo vs five of 53 [9%] with enobosarm 1 mg vs seven of 54 [13%] with enobosarm 3 mg), pneumonia (two [4%] vs two [4%] vs three [6%]), and febrile neutropenia (three [6%vs one [2%] vs none). None of these events were deemed related to study drug.
    INTERPRETATION:
    Cancer cachexia is an unmet medical need and our data suggest that use of enobosarm might lead to improvements in lean body mass, without the toxic effects associated with androgens and progestational agents.
    Click on my banner below and use code FREEBOGO to get Buy One Get One Free on all products listed under Research Pep tides and Liquids at SuperiorPeptides.com


  2. #2
    Senior Member
    BOARD REP
    Elvia1023's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    United Kingdom
    Posts
    518
    Rep Points
    402616

    In comparison to testosterone and other anabolic steroids, the advantage of SARMS, is they do not have androgenic activity in non-skeletal muscle tissues.
    Click on my banner below and use code FREEBOGO to get Buy One Get One Free on all products listed under Research Pep tides and Liquids at SuperiorPeptides.com


  3. #3
    Senior Member
    BOARD REP
    JJB1's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    USA
    Posts
    745
    Rep Points
    2593600

    I've heard that Ostarine works incredibly well in women due to it's selectively in skeletal muscle. Here is a post from another forum on Ostarine use in women:


    "I ran it a long time ago and from what I remember got good results. My wife ran it last year and got incredible results... I mean incredible! She lost bf and got stronger way stronger. It was pretty dam impressive. She actually out lifts a lot of the guys in the gym and definitely works harder than most do... I just grin when they stare at her pounding weights lol"
    Please click on my banner for the website

    Use Code: JJ25PERCOFF for 25% off your next SuperiorPeptide.com
    purchase.


  4. #4
    Senior Member
    BOARD REP
    Elvia1023's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    United Kingdom
    Posts
    518
    Rep Points
    402616






    This seems to be the most popular SARM for many from my research. Even if LGD is stronger most guys have used MK-2866 with great results.
    Click on my banner below and use code FREEBOGO to get Buy One Get One Free on all products listed under Research Pep tides and Liquids at SuperiorPeptides.com


Similar Threads

  1. Replies: 47
    Last Post: 03-28-2014, 08:48 AM
  2. Replies: 9
    Last Post: 02-11-2014, 10:47 AM
  3. anyone tried Ostarine(MK-2866 SARM)?
    By meatpistol in forum Bodybuilding Gossip
    Replies: 1
    Last Post: 10-02-2011, 03:30 AM
  4. Ostarine (MK-2866)
    By brickshthouse79 in forum Research Chemicals
    Replies: 12
    Last Post: 09-22-2011, 03:43 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
DISABLED END -->